Hostname: page-component-78c5997874-s2hrs Total loading time: 0 Render date: 2024-11-15T10:53:30.209Z Has data issue: false hasContentIssue false
  • English
  • Français

An Innovative Approach to Clinical Communication in Schizophrenia: The Approaches to Schizophrenia Communication Checklists

Published online by Cambridge University Press:  07 November 2014

Sharon G. Dott ,
Peter Weiden ,
Penelope Hopwood ,
A. George Awad ,
Jonathan S.E. Hellewell ,
John Knesevich ,
Lili Kopala ,
Alexander Miller  and
Carl Salzman
Get access Rights & Permissions [Opens in a new window]

Abstract

Side effects from antipsychotic medications can have a profound effect on patients' lives and may adversely affect their willingness to comply with treatment. Identification of side effects through improved communication between psychiatrists, other members of the healthcare team, and their patients might increase treatment compliance. The Approaches to Schizophrenia Communication (ASC) Steering Group developed two simple, practical checklists for use in the busy clinical setting. The ASC–Self-Report (ASC-SR) checklist is completed by the patient and comprises a list of the more common or clinically important side effects of antipsychotic treatment. The ASC-Clinic (ASC-C) checklist is completed by both clinician and patient together, being used as the basis for a semi-structured interview. In a multicenter pilot study set up to evaluate the utility of checklists, 86% of patients responding considered the ASC-SR to be useful in communicating their problems to psychiatrists and other members of the healthcare team. All healthcare team respondents found both checklists to be helpful when discussing side effect problems with their patients. Moreover, 41% and 47% of healthcare team respondents reported that the ASC-SR and ASC-C, respectively, had assisted them in identifying side-effect problems not previously acknowledged. Preliminary evaluation of the ASC-SR and ASC-C in this multicenter pilot study suggests that both tools were user-friendly, encouraged communication between patients and healthcare professionals about antipsychotic drug side effects, and could readily integrated into everyday clinical practice.

Type
Feature Article
Information
CNS Spectrums , Volume 6 , Issue 4: Neuropsychiatric Comorbidities: A Meeting of Minds , April 2001 , pp. 333 - 338
Copyright
Copyright © Cambridge University Press 2001

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.van Putten, T. Why do schizophrenics refuse to take their drugs? Arch Gen Psychiatry. 1974;41:67–72.CrossRefGoogle Scholar
2.Hoge, SK, Appelbaum, PS, Lawlor, T, et al.A prospective, multicentre study of patients' refusal of antipsychotic medication. Arch Gen Psychiatry. 1990;47:949.CrossRefGoogle ScholarPubMed
3.Awad, AG, Hogan, TP, Voruganti, LN, Heslegrave, RJ. Patients' subjective experiences on antipsychotic medications: implications for outcome and quality of life. Int Clin Psychopharmacol. 1995;10(suppl 3):123–132.Google ScholarPubMed
4.Day, JC, Kinderman, P, Bentall, R. A comparison of patients' and prescribers' beliefs about neuroleptic side-effects: prevalence, distress and causation. Acta Psychiatr Scand. 1998;97:93–97.CrossRefGoogle ScholarPubMed
5.Naber, D. Subjective experiences of schizophrenic patients treated with antipsychotic medication. Int Clin Psychopharmacol. 1998;13(suppl 1):841–845.CrossRefGoogle Scholar
6.Hellewell, JSE. Do we know what matters to our patients? Clear Perspectives. 1999;2:1–4.Google Scholar
7.Finn, SE, Bailey, JM, Schultz, RT, Faber, R. Subjective utility ratings of neuroleptics in treating schizophrenia. Psychol Med. 1990;20:843–854.CrossRefGoogle ScholarPubMed
8.Larsen, EB, Gerlach, J. Subjective experience of treatment, side-effects, mental state and quality of life in chronic schizophrenic out-patients treated with depot neuroleptics. Acta Psychiatr Scand. 1996;93:381–388.CrossRefGoogle ScholarPubMed
9.Weiden, P, Mann, JJ, Haas, G, Mattson, M, Frances, A. Clinical nonrecognition of neuroleptic-induced movement disorders: a cautionary study. Am J Psychiatry. 1987;144:1148–1153.Google ScholarPubMed
10.Peuskens, J, Sienaert, P, De-Heft, M. Sexual dysfunction: the unspoken side effect of antipsychotics. Eur Psychiatry. 1998;12(suppl 1):23s–30s.CrossRefGoogle Scholar
11.Weiden, P, Rapkin, B, Mott, T, et al.Rating of Medication Influences (ROMI) Scale in schizophrenia. Schizophr Bull. 1994;20(2):297–310.CrossRefGoogle ScholarPubMed
12.Awad, AG, Hogan, TP, Eastwood, R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983;13:177–183.Google Scholar
13.Hopwood, P, on behalf of the Working Group on Living with Advanced Breast Cancer Hormone Therapy. Living with advanced breast cancer: development and application of a clinical checklist for patients on endocrine therapy. Breast. 1998;7:14–21.CrossRefGoogle Scholar
14.Chaudhury, IB, Soni, SD. ASC in clinical practice: the UK experience. Clear Perspectives. 1999;2:22–24.Google Scholar
15.Miller, A, Dassori, A. ASC in US clinical practice. Clear Perspectives. 1999;2:20–21.Google Scholar